Regencell Bioscience Holdings Ltd (RGC)
CIK 1829667 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 495.9M shares as of Jun 30, 2026 (20-F).⊙
Cash runway
Self-funding
generates cash
Full breakdown: cash runway tool
Warrants
Warrants outstanding: 308,750 underlying shares, as reported Aug 19, 2021 (20-F).
Reported exercise price: $0.28 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $57,500 as of Jun 30, 2021.
Rough fully diluted estimate: 496.2M = 495.9M O/S + 308,750 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
The latest 10-Q/10-K instance document could not be checked just now, so nothing is shown rather than guessed. Try again shortly.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 495.9M | Jun 30, 2026 |
| + Warrants (aggregate, as tagged) (if exercised) | 308,750 | Aug 19, 2021 |
| Fully diluted estimate | 496.2M | +0.1% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 2 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full RGC workspace